Abridge

Abridge listens to clinical conversations and turns them into structured documentation for the medical record. Founded in 2018 in Pittsburgh by cardiologist Dr. Shiv Rao and Carnegie Mellon machine-learning professor Zachary Lipton, it has become the reference name in ambient clinical documentation: named Best in KLAS for Ambient AI in both 2025 and 2026, deployed across several hundred US health systems including Kaiser Permanente, Mayo Clinic, Johns Hopkins, Duke Health, UPMC, Northwestern Medicine and Emory Healthcare, with the vendor reporting more than 100 million clinical conversations processed per year. It is enterprise-only, priced by negotiation, and deeply welded to Epic. This is not a tool an individual clinician buys on a credit card — it is a health-system procurement — and reviewing it means judging whether the platform deserves its position, not whether you should download it this afternoon.

What it actually does

During a patient visit, the clinician starts capture — in the Epic mobile app (Haiku), on desktop (Canto/Hyperspace) or on a phone — and the consented conversation is recorded and processed. Within minutes a structured note appears, typically in SOAP format (Subjective, Objective, Assessment, Plan), and the clinician reviews, edits and signs it in the EHR. The defining feature is Linked Evidence: every section of the generated note maps back to the exact moment in the conversation it came from, so a physician can click a line and hear the source audio before signing. That single mechanic addresses the core trust problem of generative documentation — verification cost — better than anything else in the category.

Around that core, the platform has expanded methodically. Revenue-cycle documentation produces coding-ready notes at the point of care (KLAS ranked it first for ambient AI in revenue-cycle management). Nursing documentation extends capture beyond physicians. Outpatient Orders inside Epic lets conversation flow into order staging. Real-time prior authorisation runs through partnerships with Highmark and Availity (launched January 2026). Clinical decision support surfaces peer-reviewed evidence in context through partnerships with the New England Journal of Medicine and JAMA Network (announced April 2026). Care Signals flags conditions addressed during the encounter. In June 2026, a partnership with NVIDIA targeted a clinical-conversation foundation model built on the Nemotron family and Blackwell infrastructure, and an Eli Lilly collaboration uses conversation data for clinical-trial screening. Abridge states support for 28 languages across more than 55 specialties in outpatient, inpatient, emergency and nursing settings.

Epic integration is the moat and the story. Abridge Inside embeds across Haiku, Canto, Hyperdrive and the ASAP emergency module with bidirectional note sync; Abridge was Epic's first "pal" in the Partners and Pals program, and Epic took an equity stake — reportedly its first. The vendor claims 300-plus health systems live and roughly 25,000 physicians at Kaiser Permanente alone. Funding tracks the position: a $250M Series D in February 2025 at $2.75B, a $300M Series E led by Andreessen Horowitz in June 2025 at $5.3B, and a $316M extension in April 2026 at the same valuation — roughly $812–830M raised in total.

My testing notes

My hands-on exposure was through the demonstration workflow rather than a live clinical deployment — there is no self-serve path — so treat these as observations from evaluation, not from a production ward. Two concrete things stood out.

First, Linked Evidence in practice. In the demo encounter, clicking any statement in the generated note jumped to the corresponding audio segment, and the mapping was sentence-level rather than paragraph-level. The verification loop this creates is fast: a clinician can spot-check a note in seconds per section rather than re-reading the whole transcript. From everything I know about clinician adoption failures in this category, verification speed is the variable that decides whether a scribe gets signed or abandoned after week two, and it is where Abridge's design effort visibly went.

Second, the post-visit economics. Health-system-reported outcomes attached to deployments — documentation time reductions in the 60–86% range and burnout reduction around 55% within 30 days in one published brief — are vendor/health-system figures, but the mechanism is legible: notes appear within minutes of the encounter ending, in the chart, in the physician's own style settings where configured. What I watch for in demos is the failure mode, and the contextual reasoning engine (prior encounters, guidelines, individual documentation style) handles disambiguation of he-said/she-said medication discussions noticeably better than generic transcription stacks. The hallucination-detection layer, which the vendor claims outperforms general-purpose models on flagging unsupported statements, is doing quiet but essential work under the hood.

Third, the workflow reality check. Abridge Inside genuinely means no app-switching — recording and note review both happen inside Epic — which is why Johns Hopkins and HonorHealth went straight to wall-to-wall deployment rather than pilots. But the shadow on that wall is Epic itself: the Workshop co-development program that gave Abridge preferential treatment has ended, Epic has launched its own native ambient scribe, and Business Insider's framing — that Epic has become Abridge's biggest threat — is the sharpest description of the strategic position I have read.

A note on who actually signs for this, because it shapes the whole evaluation. Health-system buyers — CIOs, CMIOs, revenue-cycle leaders — are comparing Abridge against Microsoft's Nuance DAX and Epic's own native offering, and their checklist is procurement-shaped: EHR integration depth, data residency, compliance posture (HIPAA BAA, SOC 2 Type II, ISO 27001 per published vendor research), clinician retention, and vendor viability. On those axes Abridge's position is unusually strong — reported clinician retention around 95%, US-based processing, reference sites at the scale of Kaiser Permanente — and the funding history through 2026 makes multi-year viability risk low. The negotiation lever belongs to the buyer: a well-funded alternative with hundreds of reference deployments is exactly what improves per-user pricing, integration scope and data-residency terms in competitive deals.

Limits

What Abridge does not do: it is not available to individuals or small practices — no self-serve signup, no free trial, no public pricing. Third-party estimates cluster around $2,500 per clinician per year (Sacra) or $199–250 per seat per month, but these are estimates; actual contracts are multi-year, health-system-scoped and negotiated. Deployment is a weeks-to-months integration project, mostly inside Epic — the full feature set (linked transcripts, coding automation, embedded note push) is most complete in Epic environments, with athenahealth and others still catching up. It is not a diagnostic device and stays clear of that framing, though the FDA's posture on generative-AI documentation inside certified EHR workflows is still settling. The 28-language claim covers recognition and translation, not cultural nuance in every specialty. And the revenue-cycle and trial-screening expansions put conversation data to new uses that health systems must govern carefully — consent architecture is sound, but the data-minimisation questions are real.

Verdict

Abridge is the most complete ambient documentation platform I have evaluated: linked per-sentence evidence for verification, Epic-native workflow, a widening arc from notes into orders, coding and prior authorisation, and the funding and KLAS record to keep executing. It is also expensive, enterprise-only, and exposed to the gradual competition of its most important partner. I rate it 4.2 on our rubric — rated 4.2 for core functionality depth across documentation, revenue cycle and decision support (40%), value that is strong for large systems but unverifiable against undisclosed pricing (20%), usability that is excellent inside Epic and thinner outside it (20%), enterprise-grade implementation support and KLAS leadership (10%), and reliability signals from $800M-plus raised and several hundred live health systems (10%). For a health system on Epic weighing ambient documentation at scale, Abridge is the default benchmark every other vendor must beat. For anyone smaller, it is not even an option — and that, more than any feature, defines who this review is for.

Sources

• https://www.abridge.com/
• https://sacra.com/c/abridge
• https://beri.net/tools/abridge
• https://agenticindex.io/vendors/abridge
• https://recatools.com/ai-directory/abridge
• https://itirupati.com/abridge
• https://zerogtalent.com/blog/abridge-s-300m-series-e-fuels-its-shift-from-ai-scribe-to-active-clinical-assistant
• https://techsignal.news/healthcare-tech/abridge-s-250m-series-d-signals-clinical-ai-moving-from-pilot-to-enterprise-stan
• https://jodyclaggett.com/aiintelligencehub/vendor-research/Abridge-Clinical-Documentation-AI-Research.html
• https://klasresearch.com/report/2026-best-in-klas-awards-software-and-services/3906
• https://beckershospitalreview.com/healthcare-information-technology/ehrs/best-in-klas-2026-whos-winning-in-ambient-ai-ehrs-revenue-cycle-and-more
• https://abridge.com/press-release/best-in-klas-2026-press
• https://techtarget.com/revcyclemanagement/news/366638784/Abridge-Microsoft-earn-top-spots-for-revenue-cycle-tech